ARTHEx Biotech

Meet Georgina Butler (nee Croswell) of Project Management at ARTHEx Biotech! Born and raised in Cheshire, educated in Newcastle, and now living in London, Georgina brings over 20 years of international project management expertise across the pharmaceutical, biotech, and academic sectors. A pharmacologist by training, she has extensive experience in gene therapy, ophthalmology, neurology, oncology, and cardiovascular research. Since joining ARTHEx just over a year ago, Georgina has enjoyed managing the company’s first clinical trial, ArthemiR™. She has a key role in overseeing multiple aspects of clinical operations and ensures smooth coordination with multiple vendors, all while making a meaningful difference for patients living with myotonic dystrophy type 1 (DM1). Georgina enjoys spending quality time with family and friends outside of work, swimming in the sea, and savoring a hot cup of coffee. Learn more about ARTHEx here: https://lnkd.in/d_DTXkh3 #EmployeeSpotlight #Biotechnology #MyotonicDystrophy

The ARTHEx Biotech team is excited to share that Dr. beatriz llamusi, our Chief Scientific Officer and Co-Founder, will present at the upcoming TIDES: Oligonucleotides and Peptide Therapeutics Europe Annual Meeting, which will be held on November 12-14, 2024, in Hamburg, Germany. We invite you to attend Dr. Llamusí’s presentation to learn more about ARTHEx Biotech's novel delivery method to improve nucleic acid-based therapies transportation to muscle and brain, and how Arthex Biotech is leveraging this delivery strategy inr its innovative antimiRNA treatment for Myotonic Dystrophy type 1 disease. Learn more here: https://lnkd.in/g-acw_w7 #Biotechnology #MyotonicDystrophy #TIDESEurope

DM1 is an aggressive and challenging neuromuscular disorder affecting not only adults, but also children, with no approved treatment option for any age group. ATX-01, the industry’s first anti-microRNA therapeutic developed for DM1, offers a dual mechanism of action which reduces toxic DMPK mRNA while increasing MBNL protein production. With efficient delivery to muscle and brain in preclinical models, we believe ATX-01 has the potential to become a best-in-class therapy for DM1. We are pleased to continue advancing ATX-01 in our Phase I-IIa ArthemiR™ trial, with the goal to bring this therapy to patients. Learn more here: https://lnkd.in/gc6eUau8 #Biotechnology #MyotonicDystrophy #RarePediatricDiseaseDesignation

We are thrilled to announce that ATX-01 has been granted Rare Pediatric Disease (RPD) Designation from the U.S. Food and Drug Administration (FDA) for the treatment of myotonic dystrophy type 1 (DM1). This designation adds to the Orphan Drug Designation (ODD) we previously received from both U.S. and European regulatory authorities for ATX-01 in DM1.   Learn more here: https://lnkd.in/gc6eUau8 #Biotechnology #MyotonicDystrophy #RarePediatricDiseaseDesignation

On the heels of announcing the successful first patient dosing in our ArthemiR™ trial with ATX-01, we’re excited to share that ARTHEx Biotech has been featured in Nature Biopharma Dealmakers for our pioneering work in anti-microRNA therapeutics for myotonic dystrophy type 1 (DM1). Take a moment to read about how ARTHEx’s co-founders uncovered ATX-01’s dual mechanism of action, which both reduces toxic DMPK mRNA and boosts MBNL protein production, offering new hope for DM1 patients. Read more here: https://lnkd.in/dBgRPsKd #RNAInnovation #MicroRNA #Biotech #MyotonicDystrophy #DM1

We are thrilled to announce that ARTHEx Biotech has been awarded the Value Proposition Award from Bioval during the 7th Biotec Night 2024! This award is a testament to our team's hard work and innovative talents. Congratulations to all the finalists across the different categories. We are proud to be recognized alongside innovative and impactful companies in the biotechnology, biomedicine, and bioeconomy sectors. Read more here: https://lnkd.in/dqfE5CUK #MyotonicDystrophy #Biotechnology #BiovalNight2024 BIOVAL Clúster BIO Comunidad Valenciana

Meet Eliana Chali, Financial Manager at ARTHEx Biotech! Originally from La Rioja, Argentina, Eliana moved to Buenos Aires at age 7 and now resides in Valencia, Spain, with her family. Throughout her career, Eliana has explored various industries, always eager to learn and grow. Science was new to her when she joined ARTHEx, but it quickly became a passion, as she continues to learn alongside her colleagues. Her favorite part of the role is gaining a comprehensive view of the company through budget management, allowing her to understand the overall project rather than focusing on individual departments. She enjoys working with the HR team, connecting with colleagues, and appreciates the shared positive energy and commitment. A dynamic person who adapts easily to change, Eliana feels her flexibility has contributed to ARTHEx's recent growth. In her free time, she enjoys spending time with her husband and children, exploring new places, and being outdoors. A mountain lover, Eliana loves trekking and always craves the sun and fresh air! Learn more about ARTHEx here: https://lnkd.in/d_DTXkh3 #EmployeeSpotlight #Biotechnology #MyotonicDystrophy

Since the founding of ARTHEx Biotech, our team has been working tirelessly to achieve our goal of creating a new therapeutic option for persons living with DM1 and their families. Today, we are proud to announce a major milestone in our journey with the successful dosing of the first participant in our ArthemiR™ trial with ATX-01. ATX-01, the industry’s first anti-microRNA therapeutic developed for DM1, offers a dual mechanism of action, which reduces toxic DMPK mRNA while increasing MBNL protein production. By addressing both primary drivers of the disease, we are providing a comprehensive therapeutic approach that brings new hope to the DM1 community. Click here to learn more: https://lnkd.in/gg2JWx3M Visit our #Patients page on our website too: https://lnkd.in/gVNxdQVH Learn more about the dual mechanism of our AntimiR™ technology here: https://lnkd.in/gnmFvjHv #RNAInnovation #MicroRNA #Biotech #MyotonicDystrophy #DM1 #FirstPatientDosed

DM1 is a devastating rare neuromuscular disorder that causes muscle weakness and other life-limiting complications. With no disease-modifying treatments currently available, the need for a new therapeutic option is critical, and we are grateful to everyone who has helped us advance ATX-01 into clinical evaluation. In particular, we’d like to thank the trial participants and their families, the principal investigators, the study site coordinators and other site staff, for their involvement in ArthemiR™, which we hope will result in benefit to people with DM1. Click here to learn more: https://lnkd.in/gg2JWx3M Visit our #Patients page on our website too: https://lnkd.in/gVNxdQVH Learn more about the dual mechanism of our AntimiR™ technology here: https://lnkd.in/gnmFvjHv #RNAInnovation #MicroRNA #Biotech #MyotonicDystrophy #DM1 #FirstPatientDosed

#BREAKING: Today, we are thrilled to announce the first participant has been dosed in the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1), the industry’s first anti-microRNA therapeutic to be investigated in persons living with DM1. ATX-01 is an antimiR oligonucleotide designed to target microRNA 23b (miR-23b), which is involved in the pathogenesis of DM1. It has been demonstrated, in human DM1 primary myoblasts and in two murine models, that ATX-01 has a dual mechanism of action which reduces toxic DMPK mRNA and increases MBNL protein production. Click here to learn more: https://lnkd.in/gg2JWx3M Visit our #Patients page on our website too: https://lnkd.in/gVNxdQVH Learn more about the dual mechanism of our AntimiR™ technology here: https://lnkd.in/gnmFvjHv #RNAInnovation #MicroRNA #Biotech #MyotonicDystrophy #DM1 #FirstPatientDosed